|
|
Commercial Launch of Optiferrin for Mammalian Cell Culture
By Industry Article by InVitria
Publication date : Monday, 21 September 2009
InVitria today announced the launch of Optiferrin, a high performance, well-defined and animal-free recombinant transferrin for use in mammalian cell culture. Optiferrin is a cell culture supplement which supports cell growth by regulating the amount of iron transported to the cell. Since iron is required for healthy cell culture performance, it is a critical component to reach optimal performance. “Optiferrin has undergone extensive testing by our beta customers since June 2009. They have formulated Optiferrin into their cell culture media to provide maximum performance and they liked their results.
|
|  We are delighted to be able to bring this sort of value to our customers through innovations like Optiferrin,” said Scott Deeter, President & CEO of InVitria.
“Transferrin is nature’s way to deliver iron in a non-toxic manner,” said Dr. Steve Pettit, InVitria’s Director of Cell Culture Development. “Our product development, along with beta customer results, confirmed that Optiferrin delivered optimal performance without any cell damage. This alleviates customer’s concerns about animal-origin infectious contaminants or the headaches caused by addition of elemental iron and iron chelators in cell culture media,” said Dr. Pettit.
Optiferrin is a complimentary product to InVitria’s other cell culture supplement products, which include Cellastim, Lacromin, Zap-CHO and Zap-Hybridoma.
About InVitria About InVitria
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.
Want to read more?
Antibiotic Drug Discovery Platform Discovers Novel Compounds
Brain Imaging Shows Playing Tetris Leads to Both Brain Efficiency and Thicker Cortex
Amgen to Discuss Denosumab Data at Today's Advisory Committee
|
|
